EA201591213A1 - Вакцины против вируса гепатита b - Google Patents
Вакцины против вируса гепатита bInfo
- Publication number
- EA201591213A1 EA201591213A1 EA201591213A EA201591213A EA201591213A1 EA 201591213 A1 EA201591213 A1 EA 201591213A1 EA 201591213 A EA201591213 A EA 201591213A EA 201591213 A EA201591213 A EA 201591213A EA 201591213 A1 EA201591213 A1 EA 201591213A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- virus
- seq
- amino acids
- vaccines against
- cell epitope
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1223386.2A GB201223386D0 (en) | 2012-12-24 | 2012-12-24 | Vaccine |
| PCT/GB2013/053410 WO2014102540A1 (en) | 2012-12-24 | 2013-12-20 | Vaccines against hepatitis b virus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201591213A1 true EA201591213A1 (ru) | 2016-02-29 |
Family
ID=47682590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201591213A EA201591213A1 (ru) | 2012-12-24 | 2013-12-20 | Вакцины против вируса гепатита b |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10300132B2 (enExample) |
| EP (2) | EP3995146A1 (enExample) |
| JP (3) | JP6811014B2 (enExample) |
| KR (3) | KR102497063B1 (enExample) |
| CN (2) | CN104903343A (enExample) |
| CA (1) | CA2895459A1 (enExample) |
| DK (1) | DK2935313T3 (enExample) |
| EA (1) | EA201591213A1 (enExample) |
| ES (1) | ES2906110T3 (enExample) |
| GB (1) | GB201223386D0 (enExample) |
| PL (1) | PL2935313T3 (enExample) |
| WO (1) | WO2014102540A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0408164D0 (en) * | 2004-04-13 | 2004-05-19 | Immune Targeting Systems Ltd | Antigen delivery vectors and constructs |
| GB201022147D0 (en) * | 2010-12-31 | 2011-02-16 | Immune Targeting Systems Its Ltd | Formulation |
| GB201223386D0 (en) * | 2012-12-24 | 2013-02-06 | Immune Targeting Systems Its Ltd | Vaccine |
| WO2016020538A1 (en) * | 2014-08-08 | 2016-02-11 | Transgene Sa | Hbv vaccine and antibody combination therapy to treat hbv infections |
| CN106610423A (zh) * | 2015-10-26 | 2017-05-03 | 复旦大学 | 评价疫苗疗效的细胞免疫学检测试剂盒及其储存方法 |
| RS65007B1 (sr) | 2016-06-02 | 2024-01-31 | Ultimovacs Asa | Vakcina u kombinaciji sa inhibitorom imunološke kontrolne tačke za primenu u lečenju kancera |
| MY201964A (en) | 2016-06-20 | 2024-03-27 | Isa Pharmaceuticals B V | Formulation of a peptide vaccine |
| CA3085492A1 (en) * | 2017-12-19 | 2019-06-27 | Janssen Sciences Ireland Unlimited Company | Methods and apparatus for the delivery of hepatitis b virus (hbv) vaccines |
| CA3096056A1 (en) * | 2018-04-04 | 2019-10-10 | Altimmune, Inc. | T-cell inducing vaccine composition combinations and uses thereof |
| WO2020145901A1 (en) * | 2019-01-11 | 2020-07-16 | Agency For Science, Technology And Research | Use of hla-a*11:01-restricted hepatitis b virus (hbv) peptides for identifying hbv-specific cd8+ t cells |
| WO2020255018A1 (en) * | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Hepatitis b virus (hbv) vaccines and uses thereof |
| KR20220090497A (ko) * | 2019-08-29 | 2022-06-29 | 비르 바이오테크놀로지, 인코포레이티드 | B형 간염 바이러스 백신 |
| AU2020397499A1 (en) | 2019-12-07 | 2022-06-16 | Erasmus University Medical Center Rotterdam | Treatment of diseases related to hepatitis B virus |
| US20230063089A1 (en) * | 2020-01-09 | 2023-03-02 | Virion Therapeutics, Llc | Adenoviral vectors encoding hepatitis b viral antigens fused to herpes virus glycoprotein d and methods of using the same |
| WO2023085956A1 (en) * | 2021-11-09 | 2023-05-19 | Avalia Immunotherapies Limited | Novel therapeutic vaccines |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6607727B1 (en) * | 1991-08-26 | 2003-08-19 | The Scripps Research Institute | Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus |
| PT534618E (pt) * | 1991-08-26 | 2006-08-31 | Scripps Research Inst | Peptidos para inducao de respostas de linfocitos t citotoxicos ao virus da hepatite b |
| AU702367B2 (en) * | 1993-08-02 | 1999-02-18 | Scripps Research Institute, The | Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus |
| MXPA03002035A (es) | 2000-09-08 | 2004-12-13 | Epimmune Inc | Induccion de respuestas inmunes celulares al virus de la hepatitis b, usando composiciones de peptidos y de acidos nucleicos. |
| GB0408164D0 (en) | 2004-04-13 | 2004-05-19 | Immune Targeting Systems Ltd | Antigen delivery vectors and constructs |
| US10076570B2 (en) * | 2009-08-07 | 2018-09-18 | Transgene S.A. | Composition for treating HBV infection |
| GB201022147D0 (en) | 2010-12-31 | 2011-02-16 | Immune Targeting Systems Its Ltd | Formulation |
| GB201223386D0 (en) * | 2012-12-24 | 2013-02-06 | Immune Targeting Systems Its Ltd | Vaccine |
-
2012
- 2012-12-24 GB GBGB1223386.2A patent/GB201223386D0/en not_active Ceased
-
2013
- 2013-12-20 DK DK13814593.3T patent/DK2935313T3/da active
- 2013-12-20 ES ES13814593T patent/ES2906110T3/es active Active
- 2013-12-20 EA EA201591213A patent/EA201591213A1/ru unknown
- 2013-12-20 CA CA2895459A patent/CA2895459A1/en active Pending
- 2013-12-20 KR KR1020227003308A patent/KR102497063B1/ko active Active
- 2013-12-20 WO PCT/GB2013/053410 patent/WO2014102540A1/en not_active Ceased
- 2013-12-20 KR KR1020157020103A patent/KR102358621B1/ko not_active Expired - Fee Related
- 2013-12-20 EP EP21201879.0A patent/EP3995146A1/en not_active Withdrawn
- 2013-12-20 KR KR1020237003896A patent/KR102625645B1/ko active Active
- 2013-12-20 CN CN201380067602.2A patent/CN104903343A/zh active Pending
- 2013-12-20 US US14/655,041 patent/US10300132B2/en active Active
- 2013-12-20 JP JP2015548778A patent/JP6811014B2/ja not_active Expired - Fee Related
- 2013-12-20 PL PL13814593T patent/PL2935313T3/pl unknown
- 2013-12-20 CN CN202111025902.7A patent/CN114028553A/zh active Pending
- 2013-12-20 EP EP13814593.3A patent/EP2935313B1/en active Active
-
2018
- 2018-10-04 JP JP2018189011A patent/JP7187237B2/ja active Active
-
2019
- 2019-05-27 US US16/423,149 patent/US11382969B2/en active Active
-
2021
- 2021-02-19 JP JP2021025254A patent/JP7235785B2/ja active Active
-
2022
- 2022-07-09 US US17/861,189 patent/US11918645B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11918645B2 (en) | 2024-03-05 |
| US10300132B2 (en) | 2019-05-28 |
| EP2935313B1 (en) | 2021-11-24 |
| EP3995146A1 (en) | 2022-05-11 |
| KR102497063B1 (ko) | 2023-02-06 |
| KR20220019846A (ko) | 2022-02-17 |
| KR102358621B1 (ko) | 2022-02-03 |
| CN104903343A (zh) | 2015-09-09 |
| JP2021098711A (ja) | 2021-07-01 |
| JP2019034946A (ja) | 2019-03-07 |
| KR20150098676A (ko) | 2015-08-28 |
| US20230090379A1 (en) | 2023-03-23 |
| KR20230021771A (ko) | 2023-02-14 |
| DK2935313T3 (da) | 2022-02-28 |
| KR102625645B1 (ko) | 2024-01-15 |
| CN114028553A (zh) | 2022-02-11 |
| EP2935313A1 (en) | 2015-10-28 |
| JP6811014B2 (ja) | 2021-01-13 |
| JP7187237B2 (ja) | 2022-12-12 |
| US11382969B2 (en) | 2022-07-12 |
| ES2906110T3 (es) | 2022-04-13 |
| JP7235785B2 (ja) | 2023-03-08 |
| GB201223386D0 (en) | 2013-02-06 |
| JP2016505589A (ja) | 2016-02-25 |
| PL2935313T3 (pl) | 2022-05-02 |
| WO2014102540A1 (en) | 2014-07-03 |
| CA2895459A1 (en) | 2014-07-03 |
| US20160106830A1 (en) | 2016-04-21 |
| US20200016263A1 (en) | 2020-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201591213A1 (ru) | Вакцины против вируса гепатита b | |
| CY1125057T1 (el) | Anti-cd277 αντισωματα και χρησεις αυτων | |
| CY1122790T1 (el) | Αντι-ανθρωπινου ιου των θηλωματων 16 ε7 τ κυτταρου υποδοχεις | |
| MX2016002937A (es) | Vacuna oncologica. | |
| JP2014534202A5 (enExample) | ||
| JP2019527055A5 (enExample) | ||
| CL2013003634A1 (es) | Complejo que comprende una proteina de fusion que comprende, un peptido viral, peptido conector, microglobulina beta 2 , peptido conector, dominios extracelulares alfa 1, 2 y 3 de mhc de clase i y un tercer peptido conector; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso | |
| HRP20220924T1 (hr) | Imunoterapija zasnovana na pd-l1 | |
| FI2884999T4 (fi) | Menetelmä ja koostumuksia soluimmunoterapiaa varten | |
| EA201591287A1 (ru) | Вакцины, содержащие стабилизированные тримеры оболочки вируса иммунодефицита человека, и способы их применения | |
| MX2010007461A (es) | Nuevas vacunas contra multiples subtipos del virus del dengue. | |
| NZ702145A (en) | Bluetongue virus recombinant vaccines and uses thereof | |
| JP2019509029A5 (enExample) | ||
| ZA202206809B (en) | Hiv vaccines comprising one or more population episensus antigens | |
| JP2016505589A5 (enExample) | ||
| MX2013007918A (es) | Peptidos inmunogenicos monomericos y multimericos. | |
| WO2011163628A3 (en) | Dengue virus (dv) polypeptide sequences, t cell epitopes and methods and uses thereof | |
| WO2015059714A8 (en) | A viral vaccine and methods of manufacture thereof | |
| NZ702146A (en) | Peptides derived from viral proteins for use as immunogens and dosage reactants | |
| RU2019126232A (ru) | Пептиды и способы для лечения диабета | |
| ES2721159T3 (es) | Antígenos asociados a tumor independientes de MHC novedosos | |
| Azizi et al. | Mucosal HIV vaccines: a holy grail or a dud? | |
| PH12013501728A1 (en) | Combined cell based gp96-ig-siv/hiv, recombinant gp120 protein vaccination for protection from siv/hiv | |
| WO2015048796A3 (en) | Mosaic hiv envelope immunogenic polypeptides | |
| MX2019007924A (es) | Vacunas contra la influenza. |